HUBEI BIOCAUSE HEILEN PHARMACEUTICAL CO., LTD.

Hubei Biocause Heilen Pharmaceutical Co., Ltd.

301211

CNE100005782

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 28/06/2024 am IST			5-day change	1st Jan Change
14.61 ^CNY	-0.27%		-6.76%	-32.83%

20/05	Hubei Biocause Heilen Pharmaceutical Co., Ltd. Announces Implementation of Final A Share Cash Dividend for 2023, Payable on 06 June 2024	CI
17/05	Biocause Heilen Pharmaceutical's Cardiovascular Drug Passes Chinese Drug Regulator's Evaluation	MT

Hubei Biocause Heilen Pharmaceutical Co., Ltd. Announces Implementation of Final A Share Cash Dividend for 2023, Payable on 06 June 2024

May 21, 2024 at 01:04 am IST

Hubei Biocause Heilen Pharmaceutical Co., Ltd. announced implementation of final cash dividend (tax included) of CNY 4.80000000 per 10 A shares for 2023. Record date is 24 May 2024 with Ex-date on 27 May 2024 and Payment date on 27 May 2024. Net cash dividend per 10 shares after tax: CNY 4.32000000 (CNY 4.80000000- CNY 0.48000000).

Latest news about Hubei Biocause Heilen Pharmaceutical Co., Ltd.

Hubei Biocause Heilen Pharmaceutical Co., Ltd. Announces Implementation of Final A Share Cash Dividend for 2023, Payable on 06 June 2024	21/05	CI
Biocause Heilen Pharmaceutical's Cardiovascular Drug Passes Chinese Drug Regulator's Evaluation	17/05	MT
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Approves Dividend for the Year 2023	16/05	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	28/04	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	22/04	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	17/23/17	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd.(XSEC:301211) added to S&P Global BMI Index	18/23/18	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/23/24	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payment Date Is 31 May 2023	23/23/23	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022	26/23/26	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI

Chart Hubei Biocause Heilen Pharmaceutical Co., Ltd.

Duration

Period

Chart Hubei Biocause Heilen Pharmaceutical Co., Ltd.

More charts

Company Profile

Hubei Biocause Heilen Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and preparation products. The Company's products can be divided into non-steroidal anti-inflammatory, cardiovascular and anti-tumor. The API products include Ibuprofen, D-Ibuprofen, Torasemide, Milrinone, Abiraterone Acetate, Granisetron Hydrochloride, Fludarabine Phosphate and others. The preparation products include Ibuprofen Granules, Ibuprofen Tablets, Ibuprofen Pseudoephedrine Tablets, Oxaprozin Enteric Coated Tablets, Oxaprozin Enteric Coated Capsules, Torasemide Tablets and others. The Company's products are exported to India, the United States, the European Union, South Korea and other countries.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUBEI BIOCAUSE HEILEN PHARMACEUTICAL CO., LTD.	-32.83%	58Cr
ELI LILLY AND COMPANY	+55.32%	82TCr
JOHNSON & JOHNSON	-6.75%	35TCr
MERCK & CO., INC.	+13.56%	33TCr
ABBVIE INC.	+10.68%	30TCr
ASTRAZENECA PLC	+16.57%	24TCr
ROCHE HOLDING AG	+2.04%	23TCr
NOVARTIS AG	+13.31%	22TCr
AMGEN INC.	+8.48%	17TCr
PFIZER, INC.	-2.81%	16TCr